Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short term Debt: 2014-2020

Historic Short term Debt for ImmunityBio (IBRX) over the last 7 years, with Dec 2020 value amounting to $14.8 million.

  • ImmunityBio's Short term Debt rose 541.37% to $8.7 million in Q3 2021 from the same period last year, while for Sep 2021 it was $8.7 million, marking a year-over-year increase of 541.37%. This contributed to the annual value of $14.8 million for FY2020, which is 2953.09% up from last year.
  • Per ImmunityBio's latest filing, its Short term Debt stood at $14.8 million for FY2020, which was up 2,953.09% from $486,000 recorded in FY2019.
  • In the past 5 years, ImmunityBio's Short term Debt ranged from a high of $14.8 million in FY2020 and a low of $486,000 during FY2019.
  • For the 3-year period, ImmunityBio's Short term Debt averaged around $5.7 million, with its median value being $1.7 million (2018).
  • Per our database at Business Quant, ImmunityBio's Short term Debt tumbled by 71.34% in 2019 and then soared by 2,953.09% in 2020.
  • Over the past 5 years, ImmunityBio's Short term Debt (Yearly) stood at $1.8 million in 2016, then spiked by 34.80% to $2.4 million in 2017, then dropped by 28.23% to $1.7 million in 2018, then plummeted by 71.34% to $486,000 in 2019, then spiked by 2,953.09% to $14.8 million in 2020.